[{"orgOrder":0,"company":"3M Company","sponsor":"Baiya Phytopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"3M-052","moa":"||Toll-like receptor 7 | Toll-like receptor 8","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"3M Company \/ IDRI","highestDevelopmentStatusID":"4","companyTruncated":"3M Company \/ IDRI"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"7","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sls Toothpaste","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"}]

Find Clinical Drug Pipeline Developments & Deals by 3M Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 27, 2023

                          Lead Product(s) : Povidone Iodine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Recipient : University of Iowa

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 29, 2022

                          Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Baiya Phytopharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including b...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 05, 2021

                          Lead Product(s) : 3M-052,Potassium Alum

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : IDRI

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 16, 2021

                          Lead Product(s) : Chlorhexidine Gluconate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Recipient : Solventum US LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 23, 2020

                          Lead Product(s) : Sls Toothpaste

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Undisclosed

                          Recipient : Solventum US LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 12, 2020

                          Lead Product(s) : Povidone Iodine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Brigham and Women's Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 29, 2018

                          Lead Product(s) : NPWTi-d

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Recipient : KCI USA, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 18, 2018

                          Lead Product(s) : Vanish XT

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase IV

                          Recipient : University of Nebraska

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 24, 2018

                          Lead Product(s) : Chlorhexidine Gluconate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Recipient : Solventum US LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 04, 2017

                          Lead Product(s) : Tiotropium Bromide

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Solventum US LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank